- Phase I study for poor-prognosis lymphoma: augmentation of the "BEAM" regimen with escalating dose melphalan using amifostine cytoprotection and autologous hematopoietic stem cell transplantation--a preliminary report. Phillips, G.L., Abboud, C.N., Bernstein, S.H., Friedberg, J.W., Ifthikharuddin, J.J., Lancet, J.E., Liesveld, J.L., Spreng, E., Johnson, V., Chapman, M., Vesole, D.H. Semin. Oncol. (2004)